• News

Isis Files New Drug Application

Isis Pharmaceuticals Inc. reported Wednesday it has filed its new drug application for fomivirsen, a treatment of AIDS-related CMV retinitis, an infection in the retina that causes blindness. The application, which was filed with the Food and Drug Administration, will trigger an undisclosed milestone payment from Isis' partner, Swiss-based CIBA Vision Corp. CIBA Vision has exclusive worldwide distribution rights for fomivirsen, and the firm will pay Isis $20 million in pre-commercial fees and milestone payments through the time of regulatory approval in the United States and Europe. Based in Carlsbad, Isis is a drug development company.

User Response
0 UserComments